BMP1 and central precocious puberty: In addition, this study has the following limitations: the sample size was limited, requiring expansion to validate the expression patterns of BMP1 during puberty; the clinical application value of BMP1 still needs confirmation, particularly its potential as an indicator for assessing the efficacy of GnRHa treatment, previous research has shown that GnRHa therapy can reduce bone turnover markers in children with CPP by inhibiting osteoblast activity (29).